N-Acetyl Cysteine (NAC) için Inflammatory Bowel Disease (IBD) — General
D Araştırma Yalnızca ön araştırmalar mevcuttur (laboratuvar çalışmaları, olgu raporları).Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dinflammatory\u002Dbowel\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
Sonuç
Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.
Key Study Findings
Review
Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases.
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: Review of nanocatalytic antioxidation in diseases
Randomized Controlled Trial
16 weeks
Open-label
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury …
Dose: N-acetylcysteine with thiopurine
vs: Thiopurine alone (crossover)
Outcome: Liver injury markers and oxidative stress
Etki: None
None
Popülasyon: IBD patients with thiopurine-induced liver injury
Review
The emerging role of oxidative stress in inflammatory bowel disease.
Dose: None
vs: None
Outcome: Oxidative stress role in IBD pathophysiology
Etki: None
None
Popülasyon: IBD patients (Crohn's and UC)
In Vitro
4.3 weeks
Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney.
Dose: 150 mg/kg
vs: None
Outcome: inflammation markers
Etki: None
None
Popülasyon: Mice
Systematic Review
52 weeks
Vitamin D for the treatment of inflammatory bowel disease.
Dose: 400 IU/day
vs: placebo
Outcome: IBD disease activity
Etki: None
None
Popülasyon: Patients with IBD
Review
Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease …
Dose: None
vs: None
Outcome: Ferroptosis role in IBD pathogenesis
Etki: None
None
Popülasyon: IBD patients (mechanistic review)
Key Statistics
1
Çalışmalar
30
Katılımcılar
↑
Positive
D
Derece
Referenced Papers
Accounts of chemical …
2025
2 atıf
Frontiers in endocrinology
2024
165 atıf
Basic & clinical …
2024
International journal of …
2023
59 atıf
Pharmaceuticals (Basel, Switzerland)
2023
18 atıf
Oxidative medicine and …
2023
11 atıf
Vitamin D for the treatment of inflammatory bowel disease.
Systematic Review
The Cochrane database …
2023
1 atıf
Journal of nanobiotechnology
2022
206 atıf
International immunopharmacology
2022
21 atıf
Journal of biochemical …
2022
5 atıf
Medwave
2022
4 atıf
European journal of …
2021
40 atıf
Journal of inflammation …
2021
34 atıf
Journal of Crohn's …
2018
91 atıf
Redox biology
2017
34 atıf
Digestion
2016
522 atıf
Chemical research in …
2015
13 atıf
Scandinavian journal of …
2013
65 atıf
The British journal …
2012
145 atıf
World journal of …
2012
113 atıf
Pharmaceutical biology
2010
16 atıf
Digestive diseases and …
2009
49 atıf
Molecular and cellular …
2007
95 atıf
Journal of agricultural …
2007
44 atıf
The Tohoku journal …
2005
114 atıf
The Journal of …
2005
63 atıf
Journal of leukocyte …
2002
Laboratory investigation; a …
2000
116 atıf
Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability.
Other
Molecular medicine (Cambridge, …
2000
Alimentary pharmacology & …
1999
57 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 600-1,200 mg/day in divided doses
- hpyloriadjunct:
- 600 mg twice daily alongside standard triple therapy
- antioxidantsupport:
- 600-900 mg/day
Üst sınır: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| N-acetylcysteine with thiopurine | 16 weeks | Positive | -- |
| None | -- | Positive | -- |
| 150 mg/kg | 4.3 weeks | Positive | -- |
| 400 IU/day | 52 weeks | Mixed | -- |
| None | -- | Neutral | -- |
| Various antioxidant compounds | -- | Positive | -- |
| None | -- | Mixed | -- |
En iyi alım zamanı: With or without food; divide doses throughout the day
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Nausea and vomiting (most common, especially at higher doses)
- ⚠ Diarrhea
- ⚠ Unpleasant sulfur taste/odor
- ⚠ Headache
Bilinen Etkileşimler
- ● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
- ● Activated charcoal (may reduce NAC absorption)
- ● Anticoagulants (NAC may have mild antiplatelet effects)
- ● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)
Tolere edilebilir üst alım: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does N-Acetyl Cysteine (NAC) help with Inflammatory Bowel Disease (IBD) — General?
Based on 1 studies with 30 participants, there is preliminary evidence that needs more research that N-Acetyl Cysteine (NAC) may support Inflammatory Bowel Disease (IBD) — General management. Our evidence grade is D (Very Early Research).
How much N-Acetyl Cysteine (NAC) should I take for Inflammatory Bowel Disease (IBD) — General?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Inflammatory Bowel Disease (IBD) — General?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 30 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Inflammatory Bowel Disease (IBD) — General
N-Acetyl Cysteine (NAC) diğer sağlık durumları için
References
- [1] Bowen Yang et al.. Acc Chem Res. 2025. Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases. doi:10.1021/acs.accounts.5c00408 PubMed
- [2] Peter Muro et al.. Front Endocrinol (Lausanne). 2024. The emerging role of oxidative stress in inflammatory bowel disease. doi:10.3389/fendo.2024.1390351 PubMed
- [3] Dirk P van Asseldonk et al.. Basic Clin Pharmacol Toxicol. 2024. Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A … doi:10.1111/bcpt.13978 PubMed
- [4] Dickson Kofi Wiredu Ocansey et al.. Int J Mol Med. 2023. Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease (Review). doi:10.3892/ijmm.2023.5256 PubMed
- [5] Alexander V Blagov et al.. Pharmaceuticals (Basel). 2023. Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel Disease. doi:10.3390/ph16081150 PubMed
- [6] Amylly Sanuelly da Paz Martins et al.. Oxid Med Cell Longev. 2023. Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney. doi:10.1155/2023/8811463 PubMed
- [7] Chris Wallace et al.. Cochrane Database Syst Rev. 2023. Vitamin D for the treatment of inflammatory bowel disease. doi:10.1002/14651858.CD011806.pub2 PubMed
- [8] Cui Liu et al.. J Nanobiotechnology. 2022. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. doi:10.1186/s12951-022-01421-w PubMed
- [9] Liping Wang et al.. Int Immunopharmacol. 2022. High-fructose corn syrup promotes proinflammatory Macrophage activation via ROS-mediated NF-κB signaling and exacerbates colitis in mice. doi:10.1016/j.intimp.2022.108814 PubMed
- [10] Shuiliang Ruan et al.. J Biochem Mol Toxicol. 2022. Moronic acid improves intestinal inflammation in mice with chronic colitis by inhibiting intestinal macrophage polarization. doi:10.1002/jbt.23188 PubMed
- [11] Mellany Zepeda et al.. Medwave. 2022. Vitamin D supplementation in inflammatory bowel disease: a narrative review. doi:10.5867/medwave.2022.01.002525 PubMed
- [12] Justyna Kikut et al.. Eur J Nutr. 2021. Diet supporting therapy for inflammatory bowel diseases. doi:10.1007/s00394-021-02489-0 PubMed
- [13] Chengxin Shi et al.. J Inflamm Res. 2021. Selenium-Containing Amino Acids Protect Dextran Sulfate Sodium-Induced Colitis via Ameliorating Oxidative Stress and Intestinal Inflammation. doi:10.2147/JIR.S288412 PubMed
- [14] Emilio J Laserna-Mendieta et al.. J Crohns Colitis. 2018. Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis. doi:10.1093/ecco-jcc/jjx137 PubMed
- [15] Hanvit Cha et al.. Redox Biol. 2017. Increased susceptibility of IDH2-deficient mice to dextran sodium sulfate-induced colitis. doi:10.1016/j.redox.2017.05.009 PubMed
- [16] Kenichiro Takahashi et al.. Digestion. 2016. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. doi:10.1159/000441768 PubMed
- [17] Marco Pelin et al.. Chem Res Toxicol. 2015. Role of oxidative stress mediated by glutathione-s-transferase in thiopurines' toxic effects. doi:10.1021/acs.chemrestox.5b00019 PubMed
- [18] Suleyman Uraz et al.. Scand J Clin Lab Invest. 2013. N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats. doi:10.3109/00365513.2012.734859 PubMed
- [19] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
- [20] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
- [21] Thomas Sawidis et al.. Pharm Biol. 2010. Chios mastic, a natural supplement for zinc to enhance male sexuality and prostate function. doi:10.3109/13880200903029399 PubMed
- [22] Yu You et al.. Dig Dis Sci. 2009. Effect of N-acetylcysteine on the murine model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity. doi:10.1007/s10620-008-0563-9 PubMed
- [23] Julien Gommeaux et al.. Mol Cell Biol. 2007. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. doi:10.1128/MCB.01454-06 PubMed
- [24] Gabriel A Agbor et al.. J Agric Food Chem. 2007. Effect of selenium- and glutathione-enriched yeast supplementation on a combined atherosclerosis and diabetes hamster model. doi:10.1021/jf0711901 PubMed
- [25] Ali Cetinkaya et al.. Tohoku J Exp Med. 2005. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. doi:10.1620/tjem.206.131 PubMed
- [26] E Akgun et al.. J Int Med Res. 2005. Effects of N-acetylcysteine treatment on oxidative stress in acetic acid-induced experimental colitis in rats. doi:10.1177/147323000503300207 PubMed
- [27] B Salh et al.. J Leukoc Biol. 2002. Dissociated ROS production and ceramide generation in sulfasalazine-induced cell death in Raw 264.7 cells. PubMed
- [28] E Ardite et al.. Lab Invest. 2000. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. doi:10.1038/labinvest.3780077 PubMed
- [29] S Cuzzocrea et al.. Mol Med. 2000. Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability. PubMed
- [30] N J Simmonds et al.. Aliment Pharmacol Ther. 1999. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal … doi:10.1046/j.1365-2036.1999.00484.x PubMed
- [31] A D Millar et al.. Gut. 1996. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. doi:10.1136/gut.39.3.407 PubMed
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.